61825-94-3 Oxaliplatin AKSci J10621
 
 
Loading Please Wait...
  J10621    AKSci Reference Standard
Oxaliplatin
, 99%, powder
 
(trans-1,2-Cyclohexanediamine)oxalatoplatinum(II)




IDENTITY
CAS Number:61825-94-3
MDL Number:MFCD00866327
MF:C10H22N2O4Pt
MW:397.29
SPECIFICATIONS & PROPERTIES
Min. Purity Spec:99%, powder
Physical Form (at 20°C):Solid
Melting Point:285-300°C
Long-Term Storage:Store long-term at 2-8°C
DOT/IATA TRANSPORT INFORMATION
Not hazardous material

BIOLOGICAL INFO
Solubility:DMSO: 2mg/mL; H2O: <1mg/mL; EtOH: <1mg/mL
Application(s):DNA Synthesis inhibitor
Form:Free Base

REVIEW

 A platinum-based antineoplastic agent that is used in cancer chemotherapy. Oxaliplatin functions by forming both inter- and intra- strand cross links in DNA. Cross links in DNA prevent DNA replication and transcription, resulting in cell death.

REFERENCES
[1]Margiotta N, Marzano C, Gandin V, Osella D, Ravera M, Gabano E, Platts JA, Petruzzella E, Hoeschele JD, Natile G (2012). Revisiting [PtCl2(cis-1,4-DACH)]: an underestimated antitumor drug with potential application to the treatment of oxaliplatin-refractory colorectal cancer. J Med Chem. 55(16):7182-92. PMID 22788918.
[2] Pasetto LM, D'Andrea MR, Rossi E, Monfardini S: Oxaliplatin-related neurotoxicity: how and why? Crit Rev Oncol Hematol. 2006 Aug;59(2):159-68. Epub 2006 Jun 27.
[3] Graham J, Mushin M, Kirkpatrick P: Oxaliplatin. Nat Rev Drug Discov. 2004 Jan;3(1):11-2.

GLOBALLY HARMONIZED SYSTEM (GHS)

Pictograms

Signal Word
Warning

Hazard Statements
H315; H317; H319; H335; H351

Precautionary Statements
P201; P202; P261; P264; P271; P272; P280; P302+P352; P304+P340; P305+P351+P338; P308+P313; P321; P333+P313; P337+P313; P362; P403+P233; P405; P501


Current as of June 28, 2022

AKSci Reference Standards are high-purity, low-impurity compounds suitable for use as standards.


Download SDS

For research use only. Not for diagnostic or therapeutic use. Not for human use. AK Scientific, Inc. does not sell to individuals. If you are a first-time customer, please email for review at least two official business documents issued by your local jurisdiction, state/province, or country.


CATEGORIES

 APIs and Bioactives > Chemotherapeutics


PubChem